好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Effect of Glitiramer Acetate 40mg TIW on Multiple Brain MRI Parameters over One Year
Multiple Sclerosis
P5 - Poster Session 5 (5:30 PM-6:30 PM)
15-068

To determine the effect of Glatiramer Acetate 40 mg (GA 40) TIW on advanced MRI metrics.

GA 40 TIW is a disease modifying treatment, FDA approved for relapsing remitting multiple sclerosis (RRMS). It is a new formulation that greatly improves quality of life and compliance due to less injection frequency. In this advanced neuroimaging study, we investigate the effect of GA 40 on MRI metrics.
3T MRI scans of the brain were obtained at study initiation and Year 1. Neurological examination, including EDSS was performed at these two time points. Total brain (BV), normalized gray (GMV) and white matter volumes (WMV), lesional volumes (LV)  corpus callosum area (CCA), Diffuse Tensor imaging (DTI) and Magnetic Resonance Spectroscopy (MRS) data were obtained.
30 patients were recruited. Nine patients dropped out. Of the 21 patients there was no change in BV (1591.3 vs 1571.8; p=.28), WMV (780.2 vs.773.7; p= .52), GMV (811.1 vs. 798.1; p= .125), CCA (576.6 vs. 575.2; p= .39), and lesion volume (5.8 vs. 5.7; p=.69) between baseline and Year 1. Fractional Anisotropy (FA) of whole brain (WB) (.34 vs. .35; p=.71) and Normal Appearing White Matter (.50 vs. .48 p= .67), as well as Radial Diffusivity (RD) of WB (.8 vs. .79; p= .20) and NAWM (.57 vs. .56; p=.157) showed no change over one year. Lesional FA increased significantly (.31 vs. .29; p= .006)  and lesional RD (1.04 vs.1.09; p= .02) decreased at Year 1. The NAA/creatine ratio showed no significant change (2.02 vs. 2.09; p=.150). However, the EDSS did show a significant change from baseline to year 1 (1.8 vs 2.4; p=.005), possibly due to inter and intra-rater variability.

GA 40 TIW may have a neuro-protective effect in RRMS. Larger studies with longer follow-up are needed.
Authors/Disclosures
Jacob C. Rube, MD (University Health Center)
PRESENTER 		Dr. Rube has nothing to disclose.
Fen Bao Fen Bao has nothing to disclose.
Samuel Lichtman-Mikol, BA (Wayne State University) Mr. Lichtman-Mikol has nothing to disclose.
Sara Razmjou-Schwarz, MD (Mclaren Macomb hospital) No disclosure on file
Kalyan Yarraguntla, MD (University Health Center) Dr. Yarraguntla has nothing to disclose.
Carla E. Santiago-Martinez (Wayne State University) Ms. Santiago-Martinez has nothing to disclose.
Navid Seraji-Bozorgzad, MD (University of Michigan Medicine-Neurology) No disclosure on file
Evanthia Bernitsas, MD, FAAN (Wayne State School of Medicine) Dr. Bernitsas has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Bernitsas has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Vanda. The institution of Dr. Bernitsas has received research support from Roche/Genentech.